These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

544 related articles for article (PubMed ID: 26053162)

  • 1. The interrelationship of proteasome impairment and oligomeric intermediates in neurodegeneration.
    Deger JM; Gerson JE; Kayed R
    Aging Cell; 2015 Oct; 14(5):715-24. PubMed ID: 26053162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The ubiquitin proteasome system in neurodegenerative diseases: culprit, accomplice or victim?
    Dennissen FJ; Kholod N; van Leeuwen FW
    Prog Neurobiol; 2012 Feb; 96(2):190-207. PubMed ID: 22270043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ubiquitin proteasome system as a pharmacological target in neurodegeneration.
    Hol EM; Fischer DF; Ovaa H; Scheper W
    Expert Rev Neurother; 2006 Sep; 6(9):1337-47. PubMed ID: 17009921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting oligomers in neurodegenerative disorders: lessons from α-synuclein, tau, and amyloid-β peptide.
    Gadad BS; Britton GB; Rao KS
    J Alzheimers Dis; 2011; 24 Suppl 2():223-32. PubMed ID: 21460436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Degradation of misfolded proteins in neurodegenerative diseases: therapeutic targets and strategies.
    Ciechanover A; Kwon YT
    Exp Mol Med; 2015 Mar; 47(3):e147. PubMed ID: 25766616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of tau oligomers in the onset of Alzheimer's disease neuropathology.
    Cárdenas-Aguayo Mdel C; Gómez-Virgilio L; DeRosa S; Meraz-Ríos MA
    ACS Chem Neurosci; 2014 Dec; 5(12):1178-91. PubMed ID: 25268947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ubiquitin biology in neurodegenerative disorders: From impairment to therapeutic strategies.
    Kumar D; Ambasta RK; Kumar P
    Ageing Res Rev; 2020 Aug; 61():101078. PubMed ID: 32407951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preparation and characterization of neurotoxic tau oligomers.
    Lasagna-Reeves CA; Castillo-Carranza DL; Guerrero-Muoz MJ; Jackson GR; Kayed R
    Biochemistry; 2010 Nov; 49(47):10039-41. PubMed ID: 21047142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteasome Subunits Involved in Neurodegenerative Diseases.
    Fernández-Cruz I; Reynaud E
    Arch Med Res; 2021 Jan; 52(1):1-14. PubMed ID: 32962866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The ubiquitin-proteasome pathway in Parkinson's disease and other neurodegenerative diseases.
    Ross CA; Pickart CM
    Trends Cell Biol; 2004 Dec; 14(12):703-11. PubMed ID: 15564047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A common mechanism of proteasome impairment by neurodegenerative disease-associated oligomers.
    Thibaudeau TA; Anderson RT; Smith DM
    Nat Commun; 2018 Mar; 9(1):1097. PubMed ID: 29545515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ubiquitin signalling in neurodegeneration: mechanisms and therapeutic opportunities.
    Schmidt MF; Gan ZY; Komander D; Dewson G
    Cell Death Differ; 2021 Feb; 28(2):570-590. PubMed ID: 33414510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ubiquitin/proteasome pathway impairment in neurodegeneration: therapeutic implications.
    Huang Q; Figueiredo-Pereira ME
    Apoptosis; 2010 Nov; 15(11):1292-311. PubMed ID: 20131003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small ubiquitin-like modifier (SUMO) modification of natively unfolded proteins tau and alpha-synuclein.
    Dorval V; Fraser PE
    J Biol Chem; 2006 Apr; 281(15):9919-24. PubMed ID: 16464864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alpha-synuclein and tau: teammates in neurodegeneration?
    Moussaud S; Jones DR; Moussaud-Lamodière EL; Delenclos M; Ross OA; McLean PJ
    Mol Neurodegener; 2014 Oct; 9():43. PubMed ID: 25352339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Failure of ubiquitin proteasome system: risk for neurodegenerative diseases.
    Zheng C; Geetha T; Babu JR
    Neurodegener Dis; 2014; 14(4):161-75. PubMed ID: 25413678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteins in aggregates functionally impact multiple neurodegenerative disease models by forming proteasome-blocking complexes.
    Ayyadevara S; Balasubramaniam M; Gao Y; Yu LR; Alla R; Shmookler Reis R
    Aging Cell; 2015 Feb; 14(1):35-48. PubMed ID: 25510159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The ubiquitin proteasome system as a potential therapeutic target for treatment of neurodegenerative diseases.
    Opattova A; Cente M; Novak M; Filipcik P
    Gen Physiol Biophys; 2015 Oct; 34(4):337-52. PubMed ID: 26221742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Ubiquitin System in Alzheimer's Disease.
    Harris LD; Jasem S; Licchesi JDF
    Adv Exp Med Biol; 2020; 1233():195-221. PubMed ID: 32274758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SUMOylation at K340 inhibits tau degradation through deregulating its phosphorylation and ubiquitination.
    Luo HB; Xia YY; Shu XJ; Liu ZC; Feng Y; Liu XH; Yu G; Yin G; Xiong YS; Zeng K; Jiang J; Ye K; Wang XC; Wang JZ
    Proc Natl Acad Sci U S A; 2014 Nov; 111(46):16586-91. PubMed ID: 25378699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.